Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sofosbuvir/velpatasvir - Gilead Sciences

Drug Profile

Sofosbuvir/velpatasvir - Gilead Sciences

Alternative Names: Epclusa; GS 5816/sofosbuvir; GS 7977/GS 5816; SOF/VEL; Sofosbuvir/GS 5816; Velpatasvir/sofosbuvir

Latest Information Update: 28 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Carbamates; Chromans; Imidazoles; Naphthols; Phenylacetates; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in USA (PO, Granules)
  • 22 Jun 2022 Initial efficacy and adverse events data from a phase II trial in Hepatitis C presented at the International Liver Congress (ILC-2022)
  • 25 Jun 2021 Gilead Sciences completes a phase III trial for chronic Hepatitis C infection in Japan (PO) (NCT04112303)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top